Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 33Gastrointestinal 14Genitourinary 11Thoracic 7Breast 6Sarcoma 5Dermatologic 5CNS 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Other solid neoplasm 1Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 72Myelodysplastic Syndromes 34Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Biphenotypic, Acute 17Hematologic Neoplasms 14Burkitt Lymphoma 14Myeloproliferative Disorders 13Leukemia, Myelomonocytic, Chronic 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 7Myelodysplastic-Myeloproliferative Diseases 6Multiple Myeloma 6Lymphoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Primary Myelofibrosis 5Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Hairy Cell 3GATA2 Deficiency 3

Interventions

Cyclophosphamide 4sargramostim 3Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3trametinib 2pertuzumab 2pembrolizumab 2dabrafenib 2Trastuzumab 2Specimen Handling 2Palliative Care 2Methylprednisolone 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunologic Techniques 2Filgrastim 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1stenoparib 1sapanisertib 1ruxolitinib 1rucaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Specimen Handling × Other hematologic neoplasm × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04314401 2026-05-13

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Active not recruiting
1,600 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡